1 / 19

Archived File

Archived File. The file below has been archived for historical reference purposes only. The content and links are no longer maintained and may be outdated. See the OER Public Archive Home Page for more details about archived files.

luann
Download Presentation

Archived File

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Archived File The file below has been archived for historical reference purposes only. The content and links are no longer maintained and may be outdated. See the OER Public Archive Home Page for more details about archived files.

  2. Restructuring 7 study sections in 3 CSR IRGs [BST, CB, & MDCN]Don Schneider, PhDDirector, Division of Molecular and Cellular MechanismsPeer Review Advisory CommitteeJanuary 23, 2006National Institutes of HealthDepartment of Health and Human Services

  3. Timely Adjustments to Changes Changes/Problems • Complications occur, e.g., shortening the cycle • PSBR design may have been suboptimal • Workload changes beyond the ideal of 60-80 applications a cycle Fixes/Solutions • Temporary responses may involve Special Emphasis Panels • To form new study sections, CSR will involve working groups of active researchers and NIH staff

  4. Issues to be Considered • Bioengineering Sciences and Technologies IRG [BST] – small business [SBIR] applications • Cell Biology IRG [CB] – glycobiology applications • Molecular, Cellular and Developmental IRG [MDCN] – overpopulated NDBG & underpopulated BSCT

  5. BST/Bioengineering Sciences and Technologies IRG • Chief Sally Amero • IRG was launched January 2004 with six regular study sections each reviewing R01s and SBIRs (with technology in common, expect cross fertilization) • Among the relatively unique features of the study sections were that for the first time NIH organized a cluster of study sections dedicated to basic bioengineering and that all of the study sections were designed to handle regular project grant (R01) and small business grant (SBIR) applications.

  6. BST Regular Study Sections[splitting out SBIRs] • The SBIRs will be split from ISD (Instrumentation Systems and Development), BMBI (Biomaterials and Biointerfaces), and GDD (Gene and Drug Delivery Systems), where each has been handling 90-150 applications a cycle.  • MI (Microscopic Imaging), MABS (Modeling and Analysis of Biological Systems), and BDMA (Biodata Management and Analysis) will attempt to keep the SBIRs in the regular meetings; however, if cycle shortening/numbers become unmanageable the SBIRs will be split out.

  7. New SBIR SEPs • ZRG1 BSTZ 10 B – Delivery Systems and Nanotechnologies –SBIRs from GDD • ZRG1 BSTG 11 B – Materials Science and Environmental Monitoring –SBIRs from BMBI • ZRG1 BSTD 12 B – Devices and Detection Systems – SBIRs from ISD • ZRG1 BSTF 13 B – Assays and Methods Development – SBIRs from ISD

  8. CB/Cell Biology IRG • Chief Marcia Steinberg • IRG was reorganized January 2005 with five regular study sections plus a visual sciences study section (BDPE) • Review homes for glycobiology are an issue: reorganization favored ICI and CSF

  9. Glycobiology review in CB IRG • ICI/Intercellular Interactions has multiple members expert in glycobiology and is the primary review home in CB • At November Society for Glycobiology meeting in Boston, an ad hoc group of NIH staff and community members proposed MBPP/Membrane Biology and Protein Processing as a second review home

  10. Subsequent developments • The lone glycobiologist on CSF/Cell Structure and Function resigned (for lack of applications to review) • Present and future Society Presidents Ron Schnaar and Linda Baum endorsed MBPP as the second home • ICI Chair Jean Schwarzbauer sees MBPP with trafficking complementing ICI with adhesion

  11. MDCN/Molecular, Cellular and Developmental Neuroscience IRG • Chief Carole Jelsema • IRG was launched in 1998 with seven regular study sections (MDCN 1-7) • Study sections were given descriptive names in 2003, e.g., NDBG/Neurodegeneration and the Biology of Glia for MDCN-2 and BSCT/Biophysics of Synapses, Channels and Transporters for MDCN-3

  12. Notable Workload Changes • NDBG has grown particularly in oxidative/mitochondrial area to about 150 applications a cycle • BSCT has decreased to 40 or fewer applications a cycle

  13. MDCN Working Group(from community) • Paul Brehm, SUNY SB • Sandra Hewett, U Connecticut • Harry Ischiropoulos, U Pennsylvania • Robert Miller, Case Western Reserve U • Patricia Sonsalla, UMDNJ • Richard Tsien, Stanford U • Harel Weinstein, Cornell Weill

  14. MDCN Working Group(from NIH) • Chiiko Asanuma, NIMH, NIH • Lorenzo Refolo, NINDS, NIH • Steven Snyder, NIA, NIH • Ex officio: Don Schneider and Carole Jelsema • Meetings: email exchanges and December 22, 2005, teleconference call

  15. Proposal for NDBG • Continue splitting out mitochondrial applications and also those on neuron death • Rename NDGB/Neuronal Degenerative Disorders and Glial Biology • Charter the SEP and name NOMD/Neuronal Oxidative Metabolism and Death (“nomad”) • Anticipate about 75 applications each per cycle

  16. Proposal for BSCT • To prevent reversion, need one-two approach, moving applications and reviewers both in and out • Move out about 18 applications a cycle on channels, transporters, and receptors that lack a biophysical or quantitative component • Move in about 32 applications a cycle on channels, transporters, and receptors that have a biophysical or quantitative component • Rename BNS/Biophysics of Neural Systems

  17. Implications of BNS proposal • BNS would have more than 50 applications a cycle • Related MDCN study sections (NTRC, MNPS, and SYN) would lose a few applications but remain well above 50 • Proposal would make for more efficient use of reviewers, e.g., all MDCN crystallography in BNS

  18. Summary of proposed restructuring • In BST, split out SBIR applications from ISD, BMBI, & GDD and form four SBIR SEPs • In CB, retain ICI as primary locus of review for glycobiology applications and have MBPP as secondary in place of CSF • In MDCN, split NDBG into NDGB and NOMD and restructure BSCT into BNS

  19. Restructuring Study Sections(discussants) • Louise Ramm, NCRR, NIH • Edward Pugh, U Pennsylvania • Other members of PRAC

More Related